Fuzzy techniques for robust localization and tracking

Cet travail traite de l'estimation DOA dans un environement mobile. Des techniques nouvelles à base logique floue sont proposées pour améliorer les performances du système de suivi. En particulier, la capacité d'approximation de fonction sans modèle est utilisée pour obtenir une estimation angulaire des haute résolution à partir de la densité spectrale spatiale. Ces estimations sont utilisées pur améliorer la résolution du suivi. En définitive, le système de localisation et de suivi est robuste. Sa complexité est faible et il offre une résolution comparable à celle de la décomposition en valeurs singulières

Reflexiones sobre ‘Occupy. The spatial dynamics of discourse in global protest movements’ de Luisa Martin Rojo

La publicación del libro Occupy. The spatial dynamics of discourse in global protest movements, editado por Luisa Martin Rojo abre un nuevo campo para los estudios del discurso en el que se otorga centralidad al espacio en un sentido dinámico. Por este motivo, como parte del foro e-conversa (promovido por la Asociación Internacional de Estudios sobre Discurso y Sociedad EDiSo; http://www.edisoportal.org/) se planteó la lectura del capítulo introductorio (cuya traducción al español se encuentra en este número de Discurso y Sociedad) y debatir sobre algunas de las cuestiones que en él se plantean. El resultado está formado por varias contribuciones que, tomando como punto de partida el texto de Martín Rojo, reflexionan, entre otros temas, sobre las prácticas espaciales, el papel de los medios de comunicación y las redes sociales, el nuevo sujeto político emergente, las formaciones contrahegemónicas, el multilingüismo, prácticas prefigurativas, etc. De este modo, este texto dialógico es una invitación a seguir pensando el análisis del discurso desde una perspectiva novedosa ligada al espacio / The publication of the volumen Occupy. The spatial dynamics of discourse in global protest movements, edited by Luisa Martín Rojo, opens up a new field of discourse studies in which the focus lies on space, in a dynamic sense. For this reason, and as part of the forum e-conversa (hosted by the International Association of Discourse Studies and Society (EDiSo); http://www.edisoportal.org/Ediso), it was suggested to read the introduction (the Spanish translation of which is included in this issue of Discurso y Sociedad) and to debate over some of the topics presented in the book. The result consists of several contributions which, by taking Martin Rojo’s text as the starting point, reflect on spatial practices, the role of mass media and social networks, the new emerging political subject, counter-hegemonic formations, multilingualism, and prefigurative practices, among other issues. Thus, this dialogic text is an invitation to continue thinking about discourse analysis from a new perspective linked to space

Caracterización del Desbalance en Redes de Distribución Eléctricas Argentinas, a través del Factor de Desbalance Contemplando la Reglamentación Vigente

El objeto del presente trabajo es mostrar cuales son los márgenes de desbalance que aparecen y/o podrían aparecer en el sistema de distribución de la Argentina, sin violar la reglamentación nacional vigente al respecto, para compararlos con los recomendados por la normativa internacional vinculada con el tema. En tal sentido se determina el máximo valor posible que podría alcanzar la relación porcentual entre la componente de secuencia negativa y positiva (relación empleada por IEC e IEEE para evaluar el desbalance), utilizando como herramienta un algoritmo genético diseñado específicamente para cumplir con lo propuesto. Además se muestran una serie de mediciones de desbalance, obtenidas en distintos puntos del sistema de distribución eléctrica de baja tensión

Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study

Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adriamycin, and methotrexate before surgical resection of the primary tumour, followed by postoperative chemotherapy including vincristine and cyclophosphamide. Unfortunately, many patients still relapse or suffer adverse events. We examined whether common germline polymorphisms in chemotherapeutic transporter and metabolic pathway genes of the drugs used in standard osteosarcoma treatment may predict treatment response. METHODOLOGY/PRINCIPAL FINDINGS: In this study we screened 102 osteosarcoma patients for 346 Single Nucleotide Polymorphisms (SNPs) and 2 Copy Number Variants (CNVs) in 24 genes involved in the metabolism or transport of cisplatin, adriamycin, methotrexate, vincristine, and cyclophosphamide. We studied the association of the genotypes with tumour response and overall survival. We found that four SNPs in two ATP-binding cassette genes were significantly associated with overall survival: rs4148416 in ABCC3 (per-allele HR = 8.14, 95%CI = 2.73-20.2, p-value = 5.1x10(-)(5)), and three SNPs in ABCB1, rs4148737 (per-allele HR = 3.66, 95%CI = 1.85-6.11, p-value = 6.9x10(-)(5)), rs1128503 and rs10276036 (r(2) = 1, per-allele HR = 0.24, 95%CI = 0.11-0.47 p-value = 7.9x10(-)(5)). Associations with these SNPs remained statistically significant after correction for multiple testing (all corrected p-values [permutation test] </= 0.03). CONCLUSIONS: Our findings suggest that these polymorphisms may affect osteosarcoma treatment efficacy. If these associations are independently validated, these variants could be used as genetic predictors of clinical outcome in the treatment of osteosarcoma, helping in the design of individualized therapy

Developing the next generation of renewable energy technologies: an overview of low-TRL EU-funded research projects

A cluster of eleven research and innovation projects, funded under the same call of the EU’s H2020 programme, are developing breakthrough and game-changing renewable energy technologies that will form the backbone of the energy system by 2030 and 2050 are, at present, at an early stage of development. These projects have joined forces at a collaborative workshop, entitled ‘ Low-TRL Renewable Energy Technologies’, at the 10th Sustainable Places Conference (SP2022), to share their insights, present their projects’ progress and achievements to date, and expose their approach for exploitation and market uptake of their solutions

FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium

Background:Breast cancer is one of the most common malignancies in women. Genome-wide association studies have identified FGFR2 as a breast cancer susceptibility gene. Common variation in other fibroblast growth factor (FGF) receptors might also modify risk. We tested this hypothesis by studying genotyped single-nucleotide polymorphisms (SNPs) and imputed SNPs in FGFR1, FGFR3, FGFR4 and FGFRL1 in the Breast Cancer Association Consortium. Methods:Data were combined from 49 studies, including 53 835 cases and 50 156 controls, of which 89 050 (46 450 cases and 42 600 controls) were of European ancestry, 12 893 (6269 cases and 6624 controls) of Asian and 2048 (1116 cases and 932 controls) of African ancestry. Associations with risk of breast cancer, overall and by disease sub-type, were assessed using unconditional logistic regression. Results:Little evidence of association with breast cancer risk was observed for SNPs in the FGF receptor genes. The strongest evidence in European women was for rs743682 in FGFR3; the estimated per-allele odds ratio was 1.05 (95 confidence interval=1.02-1.09, P=0.0020), which is substantially lower than that observed for SNPs in FGFR2. Conclusion:Our results suggest that common variants in the other FGF receptors are not associated with risk of breast cancer to the degree observed for FGFR2. © 2014 Cancer Research UK

BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers

Background: The K3326X variant in BRCA2 (BRCA2*c.9976A&gt;T; p.Lys3326*; rs11571833) has been found to be associated with small increased risks of breast cancer. However, it is not clear to what extent linkage disequilibrium with fully pathogenic mutations might account for this association. There is scant information about the effect of K3326X in other hormone-related cancers. Methods: Using weighted logistic regression, we analyzed data from the large iCOGS study including 76 637 cancer case patients and 83 796 control patients to estimate odds ratios (ORw) and 95% confidence intervals (CIs) for K3326X variant carriers in relation to breast, ovarian, and prostate cancer risks, with weights defined as probability of not having a pathogenic BRCA2 variant. Using Cox proportional hazards modeling, we also examined the associations of K3326X with breast and ovarian cancer risks among 7183 BRCA1 variant carriers. All statistical tests were two-sided. Results: The K3326X variant was associated with breast (ORw = 1.28, 95% CI = 1.17 to 1.40, P = 5.9x10- 6) and invasive ovarian cancer (ORw = 1.26, 95% CI = 1.10 to 1.43, P = 3.8x10-3). These associations were stronger for serous ovarian cancer and for estrogen receptor–negative breast cancer (ORw = 1.46, 95% CI = 1.2 to 1.70, P = 3.4x10-5 and ORw = 1.50, 95% CI = 1.28 to 1.76, P = 4.1x10-5, respectively). For BRCA1 mutation carriers, there was a statistically significant inverse association of the K3326X variant with risk of ovarian cancer (HR = 0.43, 95% CI = 0.22 to 0.84, P = .013) but no association with breast cancer. No association with prostate cancer was observed. Conclusions: Our study provides evidence that the K3326X variant is associated with risk of developing breast and ovarian cancers independent of other pathogenic variants in BRCA2. Further studies are needed to determine the biological mechanism of action responsible for these associations

Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

Single nucleotide polymorphisms (SNPs) may modulate individual susceptibility to carcinogens. We designed a genome-wide association study to characterize individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small cell lung cancer (NSCLC), and we validated our results. We hypothesized that this strategy would enrich the frequencies of the alleles that contribute to the observed traits. We genotyped 2.37 million SNPs in 95 extreme phenotype individuals, that is: heavy smokers that either developed NSCLC at an early age (extreme cases); or did not present NSCLC at an advanced age (extreme controls), selected from a discovery set (n=3631). We validated significant SNPs in 133 additional subjects with extreme phenotypes selected from databases including >39,000 individuals. Two SNPs were validated: rs12660420 (p(combined)=5.66x10(-5); ORcombined=2.80), mapping to a noncoding transcript exon of PDE10A; and rs6835978 (p(combined)=1.02x10(-4); ORcombined=2.57), an intronic variant in ATP10D. We assessed the relevance of both proteins in early-stage NSCLC. PDE10A and ATP10D mRNA expressions correlated with survival in 821 stage I-II NSCLC patients (p=0.01 and p<0.0001). PDE10A protein expression correlated with survival in 149 patients with stage I-II NSCLC (p=0.002). In conclusion, we validated two variants associated with extreme phenotypes of high and low risk of developing tobacco-induced NSCLC. Our findings may allow to identify individuals presenting high and low risk to develop tobacco-induced NSCLC and to characterize molecular mechanisms of carcinogenesis and resistance to develop NSCLC